Adtralza (tralokinumab)

Active substance   tralokinumab
Holder LEO Pharma
Status closed
Indication Adolescent patients (12 ≤ 18 years) with severe atopic dermatitis (and a body weight < 60 kg) who are candidate for systemic treatment (including patients from the open label extension study ECZTEND LP0162-1337)
Public documents Approbation
  Approbation amendment
  Information for the patient
  Informed consent
Laste update 26/10/2023


Last updated on 27/11/2023